TY - JOUR
T1 - Selective deficiency of 1,25 dihydroxycholecalciferol. A cause of isolated skeletal resistance to parathyroid hormone
AU - Metz, S. A.
AU - Baylink, D. J.
AU - Hughes, M. R.
AU - Haussler, M. R.
AU - Robertson, R. P.
PY - 1977
Y1 - 1977
N2 - To investigate the role of vitamin D metabolites in the pathogenesis of pseudohypoparathyroidism, we studied an elderly man with a unique variant of the disease, which was characterized by hypocalcemia, elevated serum parathyroid hormone (513±13 pg per milliliter, mean ± S.E.M., normal, <450) but normal renal responses (phosphate and cyclic AMP) to exogenous parathyroid extract. Treatment with parathyroid extract did not produce a calcemic effect, suggesting an isolated skeletal hyporesponsiveness to parathyroid hormone. Although 25-hydroxyvitamin D levels were not reduced, levels of 1,25-dihydroxycholecalciferol were extremely low (0.52 ng per deciliter; normal, 3.3 ± 0.6, S.D.). Treatment with 1,25-dihydroxycholecalciferol (1 μg by mouth per day for four days) increased circulating levels to normal (4.60 ng per deciliter) and restored to normal the calcemic response to parathyroid (change in calcium, 3.0 mg per deciliter). These data suggest that 1,25-dihydroxycholecalciferol deficiency may explain the skeletal resistance, but not the renal resistance often present in classic pseudohypoparathyroidism.
AB - To investigate the role of vitamin D metabolites in the pathogenesis of pseudohypoparathyroidism, we studied an elderly man with a unique variant of the disease, which was characterized by hypocalcemia, elevated serum parathyroid hormone (513±13 pg per milliliter, mean ± S.E.M., normal, <450) but normal renal responses (phosphate and cyclic AMP) to exogenous parathyroid extract. Treatment with parathyroid extract did not produce a calcemic effect, suggesting an isolated skeletal hyporesponsiveness to parathyroid hormone. Although 25-hydroxyvitamin D levels were not reduced, levels of 1,25-dihydroxycholecalciferol were extremely low (0.52 ng per deciliter; normal, 3.3 ± 0.6, S.D.). Treatment with 1,25-dihydroxycholecalciferol (1 μg by mouth per day for four days) increased circulating levels to normal (4.60 ng per deciliter) and restored to normal the calcemic response to parathyroid (change in calcium, 3.0 mg per deciliter). These data suggest that 1,25-dihydroxycholecalciferol deficiency may explain the skeletal resistance, but not the renal resistance often present in classic pseudohypoparathyroidism.
UR - http://www.scopus.com/inward/record.url?scp=0017659242&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0017659242&partnerID=8YFLogxK
M3 - Article
C2 - 198661
AN - SCOPUS:0017659242
SN - 0028-4793
VL - 297
SP - 1084
EP - 1090
JO - New England Journal of Medicine
JF - New England Journal of Medicine
IS - 20
ER -